Select therapeutic use:

Allergies:

Indications for XOLAIR:

Chronic idiopathic urticaria in symptomatic patients despite H1-antihistamine treatment.

Limitations of Use:

Not for treating other forms of urticaria.

Adult:

Dosing is not dependent on serum total IgE level or body weight. Give by SC inj over 5–10secs into upper arm, front/middle of thighs; max 150mg per inj site. 150mg or 300mg every 4 weeks. Reevaluate periodically.

Children:

Not established.

Boxed Warning:

Anaphylaxis.

Warnings/Precautions:

History of anaphylaxis. Have medications for treating anaphylaxis available, monitor for an appropriate period of time after inj; may have delayed reaction. Discontinue if severe hypersensitivity, constellation of signs/symptoms (fever, arthralgia/arthritis, rash, and lymphadenopathy) occurs. Elevated serum IgE levels may persist for up to 1 year after stopping therapy. Patients at risk of malignancy or geohelminth infections; monitor. Eosinophilic conditions. Prefilled syringe (needle shield): latex sensitivity. Avoid abrupt cessation of systemic or inhaled corticosteroids in allergic asthma. Pregnancy. Nursing mothers.

Pharmacologic Class:

Antiasthmatic (IgE blocker).

Adverse Reactions:

Nausea, nasopharyngitis, sinusitis, upper RTI, viral upper RTI, arthralgia, headache, cough, serum IgE increase.

Note:

Enroll female patients in pregnancy exposure registry by calling (866) 4XOLAIR.

Generic Availability:

NO

How Supplied:

Single-dose vial (5mL)—1; Single-dose prefilled syringe—1

Pricing for XOLAIR

150mg vial (Qty: 1)
Appx. price $1083
GoodRx

Asthma/COPD:

Indications for XOLAIR:

Moderate-to-severe persistent asthma in patients ≥6yrs of age with a (+) skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled by inhaled corticosteroids.

Limitations of Use:

Not for relief of acute bronchospasm or status asthmaticus. Not indicated for treatment of other allergic conditions.

Adults and Children:

<6yrs: not established. Base dose and frequency on baseline serum total IgE level and body weight; see full labeling. Give by SC inj over 5–10secs into upper arm, front/middle of thighs; max 150mg per inj site. ≥6yrs: 75–375mg every 2 or 4 weeks. Reevaluate periodically.

Boxed Warning:

Anaphylaxis.

Warnings/Precautions:

History of anaphylaxis. Have medications for treating anaphylaxis available, monitor for an appropriate period of time after inj; may have delayed reaction. Discontinue if severe hypersensitivity, constellation of signs/symptoms (fever, arthralgia/arthritis, rash, and lymphadenopathy) occurs. Elevated serum IgE levels may persist for up to 1 year after stopping therapy. Patients at risk of malignancy or geohelminth infections; monitor. Eosinophilic conditions. Prefilled syringe (needle shield): latex sensitivity. Avoid abrupt cessation of systemic or inhaled corticosteroids in allergic asthma. Pregnancy. Nursing mothers.

Pharmacologic Class:

Antiasthmatic (IgE blocker).

Adverse Reactions:

Adults: arthralgia, leg/arm/general pain, fatigue, dizziness, fracture, pruritus, dermatitis, earache, serum IgE increase; Children: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bite, epistaxis.

Note:

Enroll female patients in pregnancy exposure registry by calling (866) 4XOLAIR.

Generic Availability:

NO

How Supplied:

Single-dose vial (5mL)—1; Single-dose prefilled syringe—1

Pricing for XOLAIR

150mg vial (Qty: 1)
Appx. price $1083
GoodRx